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ABSTRACT 
For natural scientists and engineers, learning from nature has tradition and is often driven by bio-inspired processes and 
materials. For example, engineers have designed multifunctional materials with hierarchical structures. Lipid bilayers, 
the principal components of cell membranes, can form vesicles, termed liposomes. Such liposomes are usually 
recognized as foreign by the immune system of a patient, which makes it challenging to use liposomes as containers for 
targeted drug delivery. There are, however, promising non-spherical, mechano-sensitive, artificial liposomes about 
100 nm in diameter, which were recently identified. These bio-inspired containers offer a wide range of applications. In 
particular, the targeted release at critically stenosed arteries formed as a result of atherosclerosis significantly reduces the 
undesired side effects such as a drop of blood pressure. It is well known that FDA-approved liposomal drugs, currently 
on the market, often induce adverse immune responses. Therefore, to exclude the hypersensitivity of the recently 
discovered mechano-sensitive liposomes, we have performed in vitro complement activation experiments and related 
animal studies with pigs. Recently, it has been shown that the drug-free Pad-PC-Pad liposomes surprisingly lack any 
complement activation. In this study, we demonstrate that nitroglycerin-loaded liposomes with relevant human 
therapeutic dosage exhibit low complement activation compared to the FDA-approved phospholipid drugs, including 
Abelcet. Furthermore, the liposomal suspensions applied are stable for a period of more than two months. Consequently, 
the non-spherical liposomes of nanometer size we have developed are promising containers for physically triggered, 
targeted drug delivery. 
Keywords: Nanotechnology, targeted drug delivery, atherosclerosis, biomimetic, liposome, shear stress, 
hypersensitivity, complement activation.  
 
1. INTRODUCTION  
Nanomedicine is at the frontline of nowadays therapy for targeted drug delivery and the global nanomedicine market 
continues to grow. It is expected to reach $528 billion by 2019 [1]. The goal of such transporting system is to safely 
assist the delivery of a pharmaceutical compound to a specific targeted within the body, increasing the therapeutic index 
of the drug and decreasing acute side effects.  
Nature has inspired most of the successfully introduced technologies, that are used in biomedical applications. Bio-
mimetical systems were developed, based on the way how the natural systems are constructed. For instance, biological 
membranes, representing highly complex and dynamic structures, are mimicked in lipid self-assembly liposomes, closed, 
spherical vesicles, trapping an aqueous solution into inner environment (see Figure 1). 
The spontaneous liposome formation is initiated when phospholipids, with two hydrophobic chains and a hydrophilic 
polar head group, are exposed to an aqueous environment. This configuration is energetically favored. Liposomes were 
firstly described by Bangham and Horne in 1964 [2]. Inspired by this architecture, liposomes appeared as a suitable 
concept for the development of drug delivery systems [3-5].  
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2. MATERIALS AND METHODS 
2.1 Materials for in vitro ELISA assay 
Pad-PC-Pad (1,3-palmitoylamido-1,3-deoxy-sn-glycero-2-phosphatidylcholine) has been synthetized following the 
previously reported protocol [6, 7]. DSPE-PEG2000 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000]) was a generous gift from Lipoid GmbH (Germany). Commercial nitroglycerin 
(NTG) solution “Perlinganit” was purchased from UCB-Pharma AG (Switzerland), Zymosan - from Sigma-Aldrich Ltd. 
(Hungary) and saline solution (0.9 %, 308 mOsm/L) - from Teva Pharmaceuticals Zrt (Hungary). Doxil and Abelcet 
were used as purchased by the Nanomedicine Research and Education Center, Semmelweis University (Hungary). 
Human serum and pig plasma samples were obtained from healthy donors at the Semmelweis University, according to an 
approved phlebotomy protocol. Until usage, the samples were stored at a temperature of -80 °C. For the determination of 
classical, alternative pathways and terminal complement complex the following ELISA kits were used: MicroVue C4d, 
Bb and SC5b-9 Plus. ELISA kits were purchased from Quidel Corp. (San Diego, CA, USA). 
2.2 Preparation of shear stress sensitive Pad-PC-Pad liposomes 
Three liposomal formulations were prepared, namely A (Pad-PC-Pad/DSPE-PEG2000), B (Pad-PC-Pad/DSPE-PEG2000) 
and C (Pad-PC-Pad). Liposomes were prepared from Pad-PC-Pad and DSPE-PEG2000 phospholipids in compliance with 
a previously reported protocol [7], using the thin film method [15, 16]. Briefly, the lyophilized phospholipids were 
dissolved in chloroform, in appropriate molar ratios: A – 95:5, B – 95:5, C – 100 mol%. The initial phospholipid 
concentration was 10 mg/mL. Then, the solvent was removed by rotatory evaporation under reduced pressure, followed 
by high-vacuum drying overnight. Three lipid films were then hydrated for a period of 30 minutes each at the 
temperature of 60 °C, with the corresponding buffer: A - 0.1 vol % NTG, B - 0.9 vol % saline, C - 0.1 vol % NTG. 
Afterwards, the liposomal suspensions were subjected to ten freeze-thaw cycles: frozen in liquid nitrogen and thawed in 
a 60 °C water bath. The liposomes were sized by multiple extrusions through Nuclepore™ track-etched polycarbonate 
membrane filters (Whatman, GE Healthcare Life Sciences, UK) of pore sizes of 400, 200, and 100 nm diameter pore 
sizes, until their diameter distribution became almost monodisperse. Multiple extrusions were performed using a barrel 
extruder Liposofast LF-50 (Avestin Inc., Canada) at 50 bar N2 pressure and a temperature of 65 °C. The samples loaded 
with Perlinganit were purified from excess of external NTG by buffer exchange using PD-10 desalting columns (GE 
Healthcare Bio-Sciences AB, Sweden), with an exclusion limit of 5,000 Da, following the manufacturer’s gravity 
protocol. The samples were stored at room temperature until use. To reach the human therapeutic dose (HTD) of 
encapsulated nitroglycerin each liposomal formulation (A, B, C) was diluted ten times (A*, B*, C*) before in vitro 
testing (cf. section 3.2). 
2.3 Characterization of lentil-shaped Pad-PC-Pad liposomes 
Measurement of size and size distribution 
The size and size distribution (polydispersity index, PDI) of the obtained liposomes was determined by triplicate 
measurements of each sample with the dynamic light scattering (DLS) technique using a DelsaNano C instrument 
(Beckman Coulter, USA) at a temperature of 25 °C. Measurements were performed on freshly prepared samples. The 
average diameter of the liposomes within each sample and standard deviations were calculated using the Smoluchowski 
model (see Table 1 below). The liposome stability over time was tested after 10, 30 and 60 days subsequent to 
preparation (see Figure 4 below). 
Measurement of zeta potential 
The zeta (ζ) potential of the samples was measured using the laser Doppler electrophoresis technique on a Zetasizer 
Nano-ZS (Malvern Instruments Ltd., UK). Liposomes samples were freshly prepared and measured with the following 
specifications: 60 s sampling time; 0.8872 cP medium viscosity; 1.33 refractive index; 173° scattering angle, using non-
invasive backscatter optics; 25 °C temperature (see Table 1 below). Data were analyzed using the Zetasizer software 
supplemented with the device. The zeta potential values were calculated using the Helmholtz–Smoluchowski's equation. 
Measurement of size and morphology 
Liposomes size and morphology were analyzed using transmission electron microscopy (TEM), using CM-100 electron 
microscope (Philips, Eindhoven, Netherlands), operating at an accelerating voltage of 80 kV. Samples were prepared by 
liposome deposition onto a 400-mesh carbon/palladium-coated copper grid (Polysciences Inc., Eppelheim, Germany), 
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substrate solution was added to each test well. Then, another incubation followed with a duration of 30 minutes (C4d) 
and 15 minutes (Bb), respectively, was done. After the incubation, the enzyme reaction was stopped chemically by 
adding 100 μL of EDTA stop solution. The optical density of the wells in each kit was measured spectrophotometrically 
with a plate reader at wavelengths of 405 (C4d) and 450 nm (Bb). 
Terminal complement complex (TCC) 
The level of the SC5b-9 complex was evaluated by MicroVue SC5b-9 Plus ELISA kit. The ELISA assay was carried out 
according to manufacturer’s instructions. Briefly, the assay wells were incubated with wash solution for a period of one 
to two minutes at a temperature between 15 and 20 °C. The samples’ aliquot of 100 μL and standards, in the 
concentration range from 0 to 185 ng/mL, were incubated in hydrated micro-assay plates for a duration of 60 minutes at 
room temperature. After incubation, the wells were washed with buffer for five times and 50 μL of HRP-conjugate was 
added to each test well. After incubation for 30 minutes at room temperature, the wells were washed with buffer for five 
times, and 100 μL of substrate solution was added to each test well. Afterwards, another incubation for a period of 
15 minutes took place. Then the enzyme reaction was stopped chemically by adding 100 μL of stop solution. The optical 
density of the wells in each kit was measured spectrophotometrically with a 96-well-plate plate reader (FLUOstar 
Omega, BMG Labtech, Germany) at wavelength of 450 nm.  
2.5 Statistical analysis 
The levels of SC5b-9, C4d and Bb in serum are expressed as mean ± S.D. For data analysis, all samples were compared 
to saline, except Zymosan. Significance of differences between the groups was determined by ordinary one-way analysis 
of variance (ANOVA), followed by Dunnett’s multiple comparison test. Differences between groups were considered 
statistically significant at P ≤ 0.05. Statistical analysis was carried out using GraphPad Prism 6 (GraphPad Software Inc., 
CA, USA). 
3. RESULTS 
3.1 Characteristics of shear-stress-sensitive Pad-PC-Pad liposomes 
Analysis of size and size distribution 
The DLS results indicate the mean diameter of the liposomes containing 5 mol% DSPE-PEG2000 corresponded to 115 nm 
(B) and 130 nm (A), while the average size of formulation composed of Pad-PC-Pad only – was above 2.5 µm (see Table 
1). The liposome stability was tested over 60 days after sample preparation. The related results are shown in Figure 4. 
Figure 4 A-B demonstrate the presence of only one peak in A and B samples after 60 days, while C shows the presence 
of three peaks. The two peaks at around 3 and 30 µm as well as the broad size distribution reveal the formation of 
liposomal aggregates. This was reflected in the PDI value, confirming that the sample was poly-disperse. 
Analysis of zeta potential 
The zeta potential was in the range from - 0.4 to + 3.1 mV (see Table 1). These values indicate that Pad-PC-Pad 
phospholipids are neutral and should exhibit a relatively low aggregation stability. 
Table 1. Properties of liposomal formulations tested in this study. Lipid concentrations of each suspension were determined 
by the phosphate test 2.0 and shown as the mean of three repeated measurements ± the relative error. DLS, PDI and ζ-
potential values were given as the mean ± standard deviation of a triplicate measurement. 
Name Lipid composition 
Lipid content 
(mg/mL) 
Average size (nm) PDI ζ-potential (mV) 
A Pad-PC-Pad/DSPE-PEG2000 8.19 ± 0.95 130.8 ± 3.7 0.10 ± 0.01 - 0.42 ± 0.4 
B Pad-PC-Pad/DSPE-PEG2000 9.18 ± 1.15 115.7 ± 0.7 0.08 ± 0.01 + 1.26 ± 0.45 
C Pad-PC-Pad 10.28 ± 0.40 2659.3 ± 247.4 0.91 ± 0.11 + 3.10 ± 0.16 
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lower count of vesicles analyzed via TEM. It should be noted that TEM analysis is a suboptimal tool to visualize 
liposomal formulations. In order to preserve initial morphology, and visualize liposomes in their native fully hydrated 
state, further imaging with a cryo-TEM is desirable. 
Human therapeutic dose of NTG 
The dosage of NTG should be adapted to the individual needs of the patient and to the response of controlled parameters, 
and the respective situation. The clinical dosage range is from 33 to 133 µg per minute [23]. Higher doses of 166 µg per 
minute are possible in rare cases [23]. In general, the results of treating acute hypertensive heart failure with intravenous 
bolus injection of 1 mg/mL of nitroglycerin were reported [24], as well as patients with severe decompensated heart 
failure with a bolus injection of 2 mg nitroglycerin [25] has been reported. Based on values obtained with the phosphate 
test for lipid concentration (Table 1), the encapsulated volume of NTG was calculated (cf. section 3.2). The quantity of 
nitroglycerin encapsulated in 10 mg/mL is about 391 µg, which is three times higher than the maximum dose. Therefore, 
a ten-fold dilution of each liposomal formulation was prepared and labeled as A*, B* and C*. Phospholipid content and 
encapsulated volume of NTG for these samples was calculated as ten times lower than initial one. However, the loading 
procedure of NTG into the liposomes was not optimized and the loading efficiency here certainly lies significantly lower 
than 100 %. 
In vitro determination of complement activation 
Overall, the level of C4d measured in all samples has shown low concentration of the protein, providing an evidence that 
complement activation of liposomes does not involve neither classical nor lectin pathways, at least to a major extent. 
Therefore, as the next step, the complement activation via alternative pathway was studied. We observed elevated levels 
of Bb concentration, caused by all the samples. This might be an indication that mainly the alternative pathway is 
involved in complement activation, caused by liposomal formulation. It was reported that increased Bb concentration in 
Doxil-sensitive sera, provides an evidence of its role in alternative pathway activation [26]. Abelcet has shown high 
activation of Bb protein, indicating a significant statistical difference. Abelcet is formulated from 1,2-dimyristoyl-sn-
glycero-3-phosphorylcholine (DMPC) and 1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol sodium salt (DMPG), 
containing amphotericin B, as active drug. A major difference between Abelcet and the rest of the samples is the shape 
and size of the particles, which could serve as a recognition factor for initiation of the complement activation. It consists 
of ribbon-like complexes, with size of 1.6 to 11.0 μm. We expected also high values of protein activation by Zymosan in 
the Bb kit, since it is an activator of the alternative pathway. The amount of Zymosan-activated protein increased and 
multiplied along the activation cascade.  
Activation of TCC was represented by the concentration of the soluble C5b-9 protein complex, formed in human sera, 
after incubation with defined samples. The obtained values were normalized to the liposome concentration of 10 mg/mL 
(A, B, C) and 1 mg/mL (A*, B*, C*). This step was applied in order to improve data integrity and better differentiate the 
impact of the liposomal formulation upon the complement activation. Also, this helps to avoid misinterpretation of 
results due to higher or lower amounts of phospholipids within the sample. 
The results of Figure 7 indicate that formulations A and C induce relatively strong complement activation. However, 
some studies suggest that if the complement activation was detected in vitro, does not necessarily mean that a patient will 
also develop HSRs in vivo. Only those with more than five- to ten-fold increased protein level may carry a risk of 
complement activation and related HSRs [27]. Such alignment of the results of A and C samples may be caused by the 
presence of NTG within the vesicles, particularly, by combination of Pad-PC-Pad loaded with NTG. Additionally, under 
the conditions used, the Pad-PC-Pad vesicles were incubated above their main transition temperature, which should lead 
to a full release of the entrapped NTG. However, when alone, NTG does not cause detectable immune reaction. Similar 
situation results were obtained for Doxil, that in the presence of doxorubicin influences the activation of the complement 
system [26]. Van den Hoven reported that prednisolone sodium phosphate encapsulated within the liposomal aqueous 
interior also causes increased chance of complement activation [28]. Besides, our recent study demonstrates that drug-
free Pad-PC-Pad do not show any significant complement activation [22], as compared to their NTD-loaded liposomal 
counterparts. As follows, incorporation of certain drugs can cause physicochemical changes to the liposomal 
formulation, carrying a risk of elevated SC5b-9 concentration. Increased levels of complement activation by C sample 
can also be correlated with the presence of aggregates, that was confirmed by the DLS measurements. As can be seen 
from the results in Figure 7, no significant changes in complement activation were seen in the sample B, which contains 
PEG2000 coupled to DSPE. Sample B showed the lowest value of SC5b-9 concentration among three concentrated 
samples, and its value was comparable to the negative control. This result was compared with our previously reported 
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data, where Pad-PC-Pad liposomes loaded with PBS did not reveal complement activation after a period of 60 minutes of 
incubation [22]. Van den Hoven also suggests that PEGylated liposomal formulations carry a low risk for causing 
hypersensitivity reactions [28]. Besides, neither reduction of PEG chain length, nor decrease of PEG density at the 
liposome surface, significantly changes activation of complement system. However, Chanan-Khan and Szebeni both 
reported that PEGylated liposomal products, such as Doxil, can induce complement activation-related hypersensitivity 
reactions [26, 27]. However, not all the patients with complement activation displayed HSRs. As explained by Chanan-
Khan, it may be related due to the involvement of certain factors, which can limit adverse consequences of activated 
complement peptides, released during complement activation [27]. The TCC activator Zymosan induces complement 
activation immediately and after 40 minutes of incubation and has reached up to 62-fold higher SC5b-9 concentration as 
compared to saline. It shall be mentioned that for this experiment one donor was found to be consistently more sensitive 
than the others. This individual could be prone to complement activation and contributes to significantly larger values 
towards the average (e.g. by factor of two for the A*, B*, C*). It is known that all types of liposomes can cause 
complement activation, which can be even enhanced due to variety of factors, such as positive or negative surface 
charge, increasing the size of liposomes, PEGylation of liposomes, presence of aggregates, presence of drugs in the 
extra-liposomal medium, high percentage (> 50 %) of cholesterol in the membrane, etc. [29]. It has been shown that 
PEGylated liposomes with 120 nm in diameter, composed of cholesterol, have shown significant increase in activation of 
Bb, indicating that size and presence of PEG molecules might be important for complement activation by triggering the 
alternative pathway [28]. Nevertheless, in our study we did not observe the effect of PEGylation on the complement 
cascade, neither in the pathway, nor in TCC tests. It is important to notice, that the type of molecule used for anchoring 
the PEG plays a certain role. In our case, we used DSPE, and not cholesterol. However, the liposomal aggregation in the 
C sample had its impact on the increased level of TCC formation. Similar statements about direct impact of the 
liposomal size, charge, and presence of PEG molecules on the complement activation, can be very subjective, as the type 
of formulation and phospholipid concentration can vary significantly from one liposomal formulation to another. To our 
knowledge, the complement system reactivity to the synthetic non-natural Pad-PC-Pad liposomes, loaded with 
nitroglycerin were reported for the first time, therefore a direct comparison with other researcher’s reports is 
complicated. 
5. CONCLUSIONS 
Liposomes can trigger initiation of both classical and alternative complement pathways. Based on the absence of 
significant changes in C4d level, involvement of the classical and lectin pathways can be excluded in the complement 
activation by Pad-PC-Pad liposomes. Instead, we observed increased levels of Bb protein, among all the samples that is 
an indicator of potential involvement of the alternative pathway. However, no statistical significance between our 
liposomal formulations and the negative control was found. Current preliminary results demonstrate C-activation after 40 
minutes of samples’ incubation. Further studies will incorporate detailed analysis of complement activation over time, at 
the various time points. Besides, determination of the SC5b-9 complex formation of NTG-loaded Pad-PC-Pad liposomes 
in porcine sera would provide additional meaningful information for future in vivo studies. 
In summary, our results indicate that nitroglycerin-loaded Pad-PC-Pad liposomes prepared of approximately 10 mg/mL 
phospholipids can carry an increased risk on hypersensitivity reaction. Nevertheless, their diluted counterparts 
demonstrate weak, biologically non-significant, complement activation only in some sensitive donors. Sensitivity for 
complement activation by liposomes is exhibited on an individual basis, suggesting that sensitive individuals could 
experience a hypersensitivity reaction. This warns about certain risk for infusion reactions of concentrated Pad-PC-Pad 
liposomes, loaded with nitroglycerin. However, as mentioned above, diluted liposomal formulations already contain 
sufficient HTD of the encapsulated drug. Therefore, the application of diluted Pad-PC-Pad liposomes is a promising 
formulation that deserves to be further investigated.  
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